{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:09:48Z","timestamp":1787022588220,"version":"build-2736575974"},"reference-count":29,"publisher":"Walter de Gruyter GmbH","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jtim-2025-0048_s_013\">\n                    <jats:title>Background and Objectives<\/jats:title>\n                    <jats:p>Recombinant human tenecteplase (TNK) tissue-type plasminogen activator (rhTNK-tPA, also named tenecteplase) is non-inferior to alteplase when given up to 4.5 hours after acute ischemic stroke (AIS) within 4.5 hours. Whether intravenous tenecteplase compared with supportive care improves the outcome of patients with AIS due to non-large vessel occlusion (non-LVO) between 4.5-24 hours is uncertain. The Tenecteplase for Acute Non-large vessel occlusion in the Extended Time Window (OPTION) trial aims to test the efficacy and safety of intravenous tenecteplase in patients presenting between 4.5-24 hours after symptom onset who have a non-LVO and evidence of salvageable tissue on perfusion imaging.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jtim-2025-0048_s_014\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>OPTION is a multicenter, prospective, randomized, open-label, blinded endpoint (PROBE) study. Patients with AIS due to non-LVO and evidence of salvageable brain tissue within 4.5-24 hour time window meeting eligibility criteria will be allocated in a 1\u22361 ratio to tenecteplase or standard medical treatment. A target mismatch profile is defined as ischemic core volume &lt;50 mL, a mismatch ratio \u22651.2, and a mismatch volume \u226510 mL. A total of 568 patients will provide &gt;80% power to detect a 12% absolute difference in the proportion of patients achieving an excellent functional outcome (modified Rankin scale [mRS] 0-1 at 90 days) at the two-sided 0.05 significance level. The primary efficacy outcome is excellent functional outcome (mRS 0-1) at 90 days. Secondary efficacy outcomes include disability level (ordinal distribution of mRS) at 90 days, functional independence (mRS 0-2) at 90 days, reperfusion at 24 hours, infarct volume at 24 hours, early clinical response at 24 hours, the National Institutes of Health Stroke Scale (NIHSS) change from baseline at 7 days\/discharge, health status and quality of life at 90 days. Safety outcomes include symptomatic intracranial hemorrhage within 36 hours, systemic bleeding within 90 days, and mortality within 90 days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jtim-2025-0048_s_016\">\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The OPTION trial (NCT05752916) will provide evidence regarding the efficacy and safety of tenecteplase 4.5 to 24 hours in patients with AIS due to non-LVO.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/jtim-2025-0048","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T13:55:56Z","timestamp":1761400556000},"page":"472-479","source":"Crossref","is-referenced-by-count":4,"title":["A multicenter, prospective, randomized, open-label, blinded endpoint trial of intravenous thrombolysis with tenecteplase for acute non-large vessel occlusion in extended time window (OPTION): Rationale and design"],"prefix":"10.1515","volume":"13","author":[{"given":"Gaoting","family":"Ma","sequence":"first","affiliation":[{"name":"Department of Neurology, Xuanwu Hospital Capital Medical University, National Center for Neurological Disorders , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Mo","sequence":"additional","affiliation":[{"name":"Department of Neurology, Xuanwu Hospital Capital Medical University, National Center for Neurological Disorders , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingting","family":"Zuo","sequence":"additional","affiliation":[{"name":"Department of Neurology, Xuanwu Hospital Capital Medical University, National Center for Neurological Disorders , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujuan","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Neurology, Xuanwu Hospital Capital Medical University, National Center for Neurological Disorders , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Xuanwu Hospital Capital Medical University, National Center for Neurological Disorders , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziying","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Xuanwu Hospital Capital Medical University, National Center for Neurological Disorders , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieying","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Xuanwu Hospital Capital Medical University, National Center for Neurological Disorders , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoyuan","family":"Lei","sequence":"additional","affiliation":[{"name":"Beijing Municipal Geriatric Medical Research Center , Beijing , China"},{"name":"Department of Evidence-Based Medicine, Xuanwu Hospital Capital Medical University , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanh N.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Radiology, Boston Medical Center, Chobanian & Avedisian School of Medicine, Boston University , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffery L.","family":"Saver","sequence":"additional","affiliation":[{"name":"Department of Neurology, Geffen School of Medicine at UCLA, UCLA Comprehensive Stroke Center, UCLA , Los Angeles, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duolao","family":"Wang","sequence":"additional","affiliation":[{"name":"Global Health Trials Unit, Liverpool School of Tropical Medicine , Liverpool , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianmei","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Neurology, Xuanwu Hospital Capital Medical University, National Center for Neurological Disorders , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingfeng","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Neurology, Xuanwu Hospital Capital Medical University, National Center for Neurological Disorders , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3075-5434","authenticated-orcid":false,"given":"Junwei","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Neurology, Xuanwu Hospital Capital Medical University, National Center for Neurological Disorders , Beijing , China"},{"name":"Beijing Municipal Geriatric Medical Research Center , Beijing , China"},{"name":"Key Laboratory for Neurodegenerative Diseases of Ministry of Education , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,10,25]]},"reference":[{"key":"2025102907595981581_j_jtim-2025-0048_ref_001","doi-asserted-by":"crossref","unstructured":"Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American heart association\/American stroke association. Stroke 2019;50:e344-418.","DOI":"10.1161\/STR.0000000000000211"},{"key":"2025102907595981581_j_jtim-2025-0048_ref_002","doi-asserted-by":"crossref","unstructured":"Tong D, Reeves MJ, Hernandez AF, Zhao X, Olson DM, Fonarow GC, et al. Times from symptom onset to hospital arrival in the Get with the Guidelines\u2014Stroke Program 2002 to 2009: temporal trends and implications. Stroke 2012;43:1912-1917.","DOI":"10.1161\/STROKEAHA.111.644963"},{"key":"2025102907595981581_j_jtim-2025-0048_ref_003","doi-asserted-by":"crossref","unstructured":"G\u00fcnkan A, Ferreira MY, Vilardo M, Scarcia L, Bocanegra-Becerra JE, Cardoso LJC, et al. Thrombolysis for ischemic stroke beyond the 4.5-hour window: a meta-analysis of randomized clinical trials. Stroke 2025;56:580-590.","DOI":"10.1161\/STROKEAHA.124.048536"},{"key":"2025102907595981581_j_jtim-2025-0048_ref_004","doi-asserted-by":"crossref","unstructured":"Xiong YY, Campbell BCV, Schwamm LH, Meng X, Jin A, Parsons MW, et al. Tenecteplase for ischemic stroke at 4.5 to 24 hours without thrombectomy. N Engl J Med 2024;391:203-212.","DOI":"10.1056\/NEJMoa2402980"},{"key":"2025102907595981581_j_jtim-2025-0048_ref_005","doi-asserted-by":"crossref","unstructured":"Albers GW, Jumaa M, Purdon B, Zaidi SF, Streib C, Shuaib A, et al. Tenecteplase for stroke at 4.5 to 24 hours with perfusion-imaging selection. N Engl J Med 2024;390:701-711.","DOI":"10.1056\/NEJMoa2310392"},{"key":"2025102907595981581_j_jtim-2025-0048_ref_006","doi-asserted-by":"crossref","unstructured":"Zhou Y, He YD, Campbell BCV, Liebeskind DS, Yuan CZ, Chen H, et al. Alteplase for acute ischemic stroke at 4.5 to 24 hours: the HOPE randomized clinical trial. JAMA 2025;334:788-797.","DOI":"10.1001\/jama.2025.12063"},{"key":"2025102907595981581_j_jtim-2025-0048_ref_007","doi-asserted-by":"crossref","unstructured":"Cheng X, Hong L, Lin LT, Churilov L, Ling YF, Yang N, et al. Tenecteplase thrombolysis for stroke up to 24 hours after onset with perfusion imaging selection: the CHABLIS-T II randomized clinical trial. Stroke 2025;56:344-354.","DOI":"10.1161\/STROKEAHA.124.048375"},{"key":"2025102907595981581_j_jtim-2025-0048_ref_008","doi-asserted-by":"crossref","unstructured":"Yan SQ, Zhou Y, Lansberg MG, Liebeskind DS, Yuan CZ, Yu H, et al. Alteplase for posterior circulation ischemic stroke at 4.5 to 24 hours. N Engl J Med 2025;392:1288-1296.","DOI":"10.1056\/NEJMoa2413344"},{"key":"2025102907595981581_j_jtim-2025-0048_ref_009","doi-asserted-by":"crossref","unstructured":"Saver JL, Chapot R, Agid R, Hassan A, Jadhav AP, Liebeskind DS, et al. Thrombectomy for distal, medium vessel occlusions: a consensus statement on present knowledge and promising directions. Stroke 2020;51:2872-2884.","DOI":"10.1161\/STROKEAHA.120.028956"},{"key":"2025102907595981581_j_jtim-2025-0048_ref_010","doi-asserted-by":"crossref","unstructured":"Kolominsky-Rabas PL, Wiedmann S, Weing\u00e4rtner M, Liman TG, Endres M, Schwab S, et al. Time trends in incidence of pathological and etiological stroke subtypes during 16 years: the Erlangen Stroke Project. Neuroepidemiology 2015;44:24-29.","DOI":"10.1159\/000371353"},{"key":"2025102907595981581_j_jtim-2025-0048_ref_011","doi-asserted-by":"crossref","unstructured":"Arsava EM, Helenius J, Avery R, Sorgun MH, Kim GM, Pontes-Neto OM, et al. Assessment of the predictive validity of etiologic stroke classification. JAMA Neurol 2017;74:419-426.","DOI":"10.1001\/jamaneurol.2016.5815"},{"key":"2025102907595981581_j_jtim-2025-0048_ref_012","doi-asserted-by":"crossref","unstructured":"Rennert RC, Wali AR, Steinberg JA, Santiago-Dieppa DR, Olson SE, Scott Pannell J, et al. Epidemiology, natural history, and clinical presentation of large vessel ischemic stroke. Neurosurgery 2019;85:S4-S8.","DOI":"10.1093\/neuros\/nyz042"},{"key":"2025102907595981581_j_jtim-2025-0048_ref_013","doi-asserted-by":"crossref","unstructured":"Waqas M, Rai AT, Vakharia K, Chin F, Siddiqui AH. Effect of definition and methods on estimates of prevalence of large vessel occlusion in acute ischemic stroke: a systematic review and meta-analysis. J Neurointerv Surg 2020;12:260-265.","DOI":"10.1136\/neurintsurg-2019-015172"},{"key":"2025102907595981581_j_jtim-2025-0048_ref_014","doi-asserted-by":"crossref","unstructured":"Duloquin G, Graber M, Garnier L, Crespy V, Comby PO, Baptiste L, et al. Incidence of acute ischemic stroke with visible arterial occlusion: a population-based study (Dijon stroke registry). Stroke 2020;51:2122-2130.","DOI":"10.1161\/STROKEAHA.120.029949"},{"key":"2025102907595981581_j_jtim-2025-0048_ref_015","doi-asserted-by":"crossref","unstructured":"Thomalla G, Boutitie F, Ma H, Koga M, Ringleb P, Schwamm LH, et al. Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data. Lancet 2020;396:1574-1584.","DOI":"10.1016\/S0140-6736(20)32163-2"},{"key":"2025102907595981581_j_jtim-2025-0048_ref_016","doi-asserted-by":"crossref","unstructured":"Thomalla G, Simonsen CZ, Boutitie F, Andersen G, Berthezene Y, Cheng B, et al. MRI-guided thrombolysis for stroke with unknown time of onset. N Engl J Med 2018;379:611-622.","DOI":"10.1056\/NEJMoa1804355"},{"key":"2025102907595981581_j_jtim-2025-0048_ref_017","doi-asserted-by":"crossref","unstructured":"Ma H, Campbell BCV, Parsons MW, Churilov L, Levi CR, Hsu C, et al. Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke. N Engl J Med 2019;380:1795-1803.","DOI":"10.1056\/NEJMoa1813046"},{"key":"2025102907595981581_j_jtim-2025-0048_ref_018","doi-asserted-by":"crossref","unstructured":"Berge E, Whiteley W, Audebert H, De Marchis GM, Fonseca AC, Padiglioni C, et al. European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke. Eur Stroke J 2021;6:I-LXII.","DOI":"10.1177\/2396987321989865"},{"key":"2025102907595981581_j_jtim-2025-0048_ref_019","doi-asserted-by":"crossref","unstructured":"Menon BK, Buck BH, Singh N, Deschaintre Y, Almekhlafi MA, Coutts SB, et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial. Lancet 2022;400:161-169.","DOI":"10.1016\/S0140-6736(22)01054-6"},{"key":"2025102907595981581_j_jtim-2025-0048_ref_020","doi-asserted-by":"crossref","unstructured":"Wang Y, Li S, Pan Y, Li H, Parsons MW, Campbell BCV, et al. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial. Lancet 2023;401:645-654.","DOI":"10.1016\/S0140-6736(22)02600-9"},{"key":"2025102907595981581_j_jtim-2025-0048_ref_021","doi-asserted-by":"crossref","unstructured":"Meng X, Li SY, Dai HG, Lu GZ, Wang WW, Che FY, et al. Tenecteplase vs alteplase for patients with acute ischemic stroke: the ORIGINAL randomized clinical trial. JAMA 2024;332:1437-1445.","DOI":"10.1001\/jama.2024.14721"},{"key":"2025102907595981581_j_jtim-2025-0048_ref_022","doi-asserted-by":"crossref","unstructured":"Muir KW, Ford GA, Ford I, Wardlaw JM, McConnachie A, Greenlaw N, et al. Tenecteplase versus alteplase for acute stroke within 4\u00b75 h of onset (ATTEST-2): a randomised, parallel group, open-label trial. Lancet Neurol 2024;23:1087-1096.","DOI":"10.1016\/S1474-4422(24)00377-6"},{"key":"2025102907595981581_j_jtim-2025-0048_ref_023","doi-asserted-by":"crossref","unstructured":"Parsons MW, Yogendrakumar V, Churilov L, Garcia-Esperon C, Campbell BCV, Russell ML, et al. Tenecteplase versus alteplase for thrombolysis in patients selected by use of perfusion imaging within 4.5 h of onset of ischaemic stroke (TASTE): a multicentre, randomised, controlled, phase 3 non-inferiority trial. Lancet Neurol 2024;23:775-786.","DOI":"10.1016\/S1474-4422(24)00206-0"},{"key":"2025102907595981581_j_jtim-2025-0048_ref_024","unstructured":"Chinese Society of Neurology CSS. [Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2023]. Chin J Neurol 2024;57:523-559."},{"key":"2025102907595981581_j_jtim-2025-0048_ref_025","unstructured":"Chinese Society of Neurology CSS. [Chinese guideline for the secondary prevention of ischemic stroke and transient ischemic attack 2022]. Chin J Neurol 2022;55:1071-1110."},{"key":"2025102907595981581_j_jtim-2025-0048_ref_026","doi-asserted-by":"crossref","unstructured":"von Kummer R, Broderick JP, Campbell BCV, Demchuk A, Goyal M, Hill MD, et al. The Heidelberg bleeding classification: classification of bleeding events after ischemic stroke and reperfusion therapy. Stroke 2015;46:2981-2986.","DOI":"10.1161\/STROKEAHA.115.010049"},{"key":"2025102907595981581_j_jtim-2025-0048_ref_027","doi-asserted-by":"crossref","unstructured":"Campbell BCV, Ma H, Ringleb PA, Parsons MW, Churilov L, Bendszus M, et al. Extending thrombolysis to 4.5-9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data. Lancet 2019;394:139-147.","DOI":"10.1016\/S0140-6736(19)31053-0"},{"key":"2025102907595981581_j_jtim-2025-0048_ref_028","doi-asserted-by":"crossref","unstructured":"Becks MJ, Manniesing R, Vister J, Pegge SAH, Steens SCA, van Dijk EJ, et al. Brain CT perfusion improves intracranial vessel occlusion detection on CT angiography. J Neuroradiol 2019;46:124-129.","DOI":"10.1016\/j.neurad.2018.03.003"},{"key":"2025102907595981581_j_jtim-2025-0048_ref_029","doi-asserted-by":"crossref","unstructured":"Sousa JA, Sondermann A, Bernardo-Castro S, Varela R, Donato H, Sargento-Freitas J. CTA and CTP for detecting distal medium vessel occlusions: a systematic review and meta-analysis. AJNR Am J Neuroradiol 2023;45:51-56.","DOI":"10.3174\/ajnr.A8080"}],"container-title":["Journal of Translational Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jtim-2025-0048\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jtim-2025-0048\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T08:00:49Z","timestamp":1761724849000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jtim-2025-0048\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":29,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,10,25]]},"published-print":{"date-parts":[[2025,10,29]]}},"alternative-id":["10.1515\/jtim-2025-0048"],"URL":"https:\/\/doi.org\/10.1515\/jtim-2025-0048","relation":{},"ISSN":["2224-4018"],"issn-type":[{"value":"2224-4018","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,1]]}}}